Leukocyte infiltration into the brain contributes to the development of ischemic brain damage and is mediated by endothelial/leukocyte adhesion molecules, cytokines, and che mokines released by ischemic brain cells. In this study, we provide evidence that human astrocytes (FHAs) subjected to in vitro hypoxia produce proinflammatory mediator(s) capable of up-regulating inflammatory genes, including intercellular ad hesion molecule-I, interleukin (IL)-II3, tumor necrosis factor a, IL-8, and monocyte chemotactic protein-l (MCP-I) in hu man cerebromicrovascular endothelial cells (HCECs). FHAS were exposed to hypoxia in an anaerobic chamber for 4 hours, followed by reoxygenation for 24 hours. Astrocyte-conditioned media (ACM) collected from normoxic FHAS or FHAS sub jected to hypoxiaireoxygenation were applied to HCEC cul tures for 4 to 24 hours. Semiquantitative reverse transcription polymerase chain reaction, immunocytochemistry, and en zyme-linked immunosorbent assay demonstrated up-regulation of intercellular adhesion molecule-l in HCECs exposed to hyp oxic ACM. A pronounced elevation in cytokine IL-113 and Clinical and experimental evidence has implicated brain intlammation in the development of secondary ischemic brain damage in brain ischemia and trauma (del
tumor necrosis factor-a, and chemokine IL-8 and MCP-I mRNA, accompanied by increased release of immunoreactive cytokines and chemokines into cell media was observed in HCECs exposed to hypoxic ACM. Hypoxiaireoxygenation in duced a transient (4 to 18 hours of reoxygenation) up regulation of IL-113 mRNA in FHAS and a two-to threefold increase in IL-113 levels secreted into ACM. Pretreatment of FHAS with 10 j.Lmol/L dexamethasone inhibited both hypoxia induced expression/secretion of IL-113 and the ability of hyp oxic ACM to induce inflammatory phenotype in HCECs. The ability of hypoxic ACM to up-regulate inflammatory genes in HCECs was inhibited in the presence of IL-I receptor antago nist (IL-IRa) and by pretreating ACM with the blocking anti IL-113 antibody. These findings strongly implicate IL-113 se creted by hypoxic astrocytes in triggering inflammatory acti vation of HCECs and thereby influencing inflammatory responses at the site of the blood-brain barrier. Key Words: Hypoxia-Human astrocytes-Human brain endothelial cells-Cytokines-IL-II3-Chemokines-ICAM -I. et aI., 1986; Kim, 1996; Kochanek and Hallenbeck, 1992; Ransohoff and Tani, 1998) . Brain intlammation after ischemia develops as a consequence of two related processes, i.e., the activation of glial cells and resident perivascular/parenchymal macrophages (Giulian, 1990) and the mobilization (del Zoppo et aI., 199 1) and infil tration of peripheral intlammatory cells into the brain (Barone et aI., 199 1; Hallenbeck et aI., 1986; Matsuo et aI., 1994) . Activated glia has been shown to produce numerous prointlammatory mediators (Giulian, 1990; Stoll et aI., 1998) , including interleukin (IL)-I!3 (Lee et aI., 1993) . Cerebral endothelium undergoes a "pro intlammatory" activation leading to increased interac tions with peripheral leukocytes (del . Mo bilization of polymorphonuclear leukocytes in ischemic microvessels occurs as early as 30 minutes after the middle cerebral artery occlusion (MCAO) in rat and is followed by accumulation of circulating monocytes within capillaries after 4 to 6 hours (Garcia et aI., 1994) . Both neutrophils and monocytes subsequently infiltrate the brain tissue (Barone et aI., 199 1; Garcia et aI., 1994) and can be detected in the brain as late as 7 days after the insult. The process of leukocyte trafficking across the blood-brain barrier is regulated by mediators produced! released by brain parenchymal cells, cerebral endothelial cells (CECs), and leukocytes (Baggiolini, 1998; Barone et ai., 199 1; Feuerstein et ai., 1998; Kishimoto and Roth lein, 1994; Ransohoff and Tani, 1998) .
Cytokines, including IL-II3, are central regulators of inflammatory responses in peripheral tissues (Colotta et ai., 1998; Dinarello, 1996 Dinarello, , 1998 . IL-113 is synthesized as a precursor protein, pro-IL-II3, which is then cleaved by IL-l-converting enzyme (ICE) into an active IL-113 (Co lotta et ai., 1998) . IL-113 binds two types of receptors, a signaling type I (IL-IRI) receptor, and type II (IL-IRIl) receptor, a decoy that inhibits IL-l activity (Colotta et ai., 1998; Dinarello, 1998) . IL-113 has been shown to induce the expression of adhesion molecules including intercellular adhesion molecule-I (ICAM-I), vascular cell adhesion molecule-I, and E-selectin in human CECs (Stanimirovic et ai., 1997b,c) . Up-regulation of both en dothelial cell and leukocyte adhesion molecules by isch emia is necessary for leukocyte rolling and adhesion to vascular walls (Kim, 1996; Kishimoto and Rothlein, 1994) . Subsequent leukocyte transmigration across the endothelial cell barrier also requires the presence of che motactic gradients (Baggiolini, 1998; Baggiolini et ai., 1997; Hausmann et ai., 1998; Rollins, 1997) .
Inflammatory activation of CECs in cerebral ischemia probably starts via signals activated by hypoxia/ischemia in CECs themselves and is then sustained by paracrine mediators released by neighboring parenchymal cells. Astrocyte end-feet envelope brain capillaries and close interactions between these two cell types have been im plicated in the regulation of phenotypic properties of CECs (Abbott et ai., 1992; Cancilla et ai., 1993) , CEC proliferation and angiogenesis (Cancilla et ai., 1993; Sta nimirovic et ai., 1995) , CEC production of anticoagulant factors (Tran et ai., 1999) , and the blood-brain barrier permeability (Cancilla et aI., 1993) . Astrocyte/ endothelial proximity and interactions may also be im portant in regulating inflammatory responses at the site of the blood-brain barrier. Astrocytes have been shown to produce cytokines, chemokines, and adhesion mol ecules when stimulated with cytokines (Aloisi et ai., 1995; Lee et ai., 1993 Lee et ai., , 1998 . We have recently demon strated that both human CECs and human astrocytes sub jected to a simulated ischemia in vitro secrete bioactive chemokines IL-8 and monocyte chemotactic protein-l (MCP-l) and other neutrophil chemoattractants (Zhang et ai., 1999) .
In the present study, we provide evidence that human astrocytes exposed to in vitro hypoxia express and re lease bioactive IL-I I3, which triggers a pro inflammatory activation of human brain endothelium in a paracrine manner.
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MATERIALS AND METHODS

Cell cultures
The protocols used in these studies have been approved by the Human Research Ethics Committees of the National Re search Council of Canada and the Montreal Neurological In stitute (McGill University).
Primary human cerebromicrovascular endothelial cell cul tures (HCECs) were isolated and maintained by using a modi fication (Stanimirovic et aI., 1996) of the procedures described originally by Gerhart et al. (1988) . The cells were grown at 37°C in a 5% CO2 atmosphere in a medium containing 65% Dulbecco's modified Eagle's medium (DME) (4,500 mg/L glu cose), 10% fetal bovine serum (FBS; HyClone, Logan, UT, U.S.A.), 5% human serum (Sigma, St. Louis, MO, U.S.A.), 20% murine melanoma cell-conditioned media, 5 J.1g/mL insu lin, 5 J.1g/mL transferrin, 5 J.1g/mL selenium, and 10 J.1g/mL endothelial cell growth supplement (Collaborative Biomedical Products, Bedford, MA, U.S.A.). Both primary and propagated cultures were routinely characterized for the expression of fac tor VIII-related antigen and the absence of smooth muscle cell ex-actin as described previously (Stanimirovic et aI., 1996) . Pas sages 2 to 6 of HCECs were used for the experiments in this study.
Primary fetal (10 to 18 weeks of gestation) human astrocyte (FHAS) cultures were generously provided by Dr. J. Antel (Montreal Neurological Institute, Montreal, QC, Canada). These cultures were prepared by using previously described procedures (Y ong et aI., 1992) . FHAS were grown in DME containing 10% FBS (HyClone, Logan, UT, U.S.A.) and anti biotics (GibcoBRL, Burlington, ON, Canada) in an atmosphere of 5% COi95% air at 37°C. More than 95% of cells in FHAS cultures were immunopositive for the glial fibrillary acidic pro tein. Passages 2 to 6 of FHAS were used in this study.
In vitro hypoxia FHAS were grown on 35-mm dishes to 90% confluence in complete medium. For the experiments, media were removed and cells washed in a Hanks' balanced salt solution (HBSS; GibcoBRL). A serum-free DME was then added to the cells and they were subjected to severe hypoxia «2% oxygen) for 4 hours in an anaerobic chamber (Anaerobic System Model 1024, Forma Scientific, Fisher Scientific, Nepean, Canada) equipped with a humidified, temperature-controlled incubator directly accessible within the chamber. The entire system was purged with 95% N2/5% CO2 atmosphere. At the end of the hypoxic period, the media were removed, cells washed twice in HBSS, and 1.5 mL of DME containing 1 % FBS was added to the cells. The cells were reoxygenated in ambient air at 37°C and both media and cells were harvested after 4, 8, 18, or 24 hours. We have previously shown that these conditions do not affect vi ability of astrocyte cultures (Stanimirovic et aI., 1997a) .
Astrocyte-conditioned media
FHAS grown in tissue culture flasks (Nalge NUNC Interna tional, Rochester, NY, U.S.A.) were subjected to hypoxia as above, washed twice in HBSS, and reoxygenated for 24 hours in 12 mL of DME containing 1 % FBS. The media [astrocyte conditioned media (ACM)] were then collected and applied immediately to HCECs as described below. Control FHAS were not subjected to hypoxia but underwent the same media changes and ACM collection as hypoxic FHAS.
ACM collected from either normoxic or hypoxic FHAS was applied to HCECs grown in 35-mm dishes (1 x 10 5 cells/dish) to 90% confluence. HCECs were incubated with ACM for 4, 8, 18, and 24 hours. The media were then collected and HCECs were prepared for immunocytochemistry and biochemical ana lyzes. The supernatants of media and cell extracts were stored at -80°C until use.
Immunocytochemistry
The expression of ICAM-I in HCECs was detected by im munocytochemistry and enzyme-linked immunosorbent assay (ELISA) by using a monoclonal antibody to human ICAM-l (Clone CD54; Upstate Biotechnology, Lake Placid, NY, U.S.A.). The specificity of the antibody has been confirmed previously in studies using purified ICAM-l (Makgoba et a!., 1988) . The antibody also recognized a single band on a West ern blot of HCEC lysate (data not shown).
For immunocytochemistry, HCECs grown on 10 j.Lg/mL hu man fibronectin-coated glass coverslips were washed in HBSS FIG. 1. The effects of the media con ditioned by either control (Con-ACM) or hypoxic (Hyp-ACM) fetal human astrocytes (FHAS) on the expression of ICAM-1 mRNA in human cerebral endothelial cells (HCEC). HCEC were exposed to Con-ACM or Hyp-ACM prepared as described in Materials and Methods for the indicated periods of time. ICAM-1 mRNA expression was determined by RT-PCR using f)-actin as an internal control. Vol umes of ICAM-1 bands for Con-ACM (open bars) and Hyp-ACM (closed bars) were expressed as a percent age of f)-actin bands. Each bar rep resents the mean ± SO derived from four separate gels. *indicates a sig nificant difference (P < 0.01; analysis of variance followed by the Fisher's protected least square difference multiple comparisons) from corre sponding time-matched Con-ACM levels. 
and incubated at room temperature with the primary anti ICAM-I antibody (2 j.Lg/mL) for 40 minutes. The nonspecific binding was blocked by 4% goat serum. Cells were then washed in HBSS and incubated for 1 hour with a 1:50 dilution of a 4-nm colloidal gold particle-conjugated goat antimouse IgG antibody. Coverslips were then fixed for 30 seconds with 9.25% formaldehyde and 45% acetone in HBSS, washed, and incubated in a silver-enhancing solution (IntenSETM; Amer sham Pharmacia Biotech, Piscataway, NJ, U.S.A.) for 25 min utes. Coverslips were then washed and counterstained with Giemsa stain for 15 minutes. Nonspecific staining was deter mined by (1) omitting the secondary antibody from the proce dure, and (2) by replacing primary anti-ICAM-I antibody with the isotype-matched antibody to glial fibrillary acidic protein (Accurate Chemical and Scientific, Westbury, NY, U.S.A.). Duration of exposure to ACM (h)
Con
ELISA An ELISA was used to quantify levels of ICAM-I expres sion in HCECs and levels of immunoreactive IL-8, MCP-I, and IL-I J) in FHAS-conditioned media and in media collected from differently treated HCEC.
ELISA for ICAM-I was performed essentially as described by Stanimirovic et al. (1997b) . In brief, HCEC cultures grown in 96-well microtiter plates (2 x 10 4 cellsll 00 fLLlwell), at 37°C in 5% CO2, were sequentially incubated with a primary monoclonal antihuman ICAM-I antibody (2 fLg/mL; clone CD54; Upstate Biotechnology) for I hour at 37°C, followed by 1:500 diluted peroxidase-conjugated goat antimouse IgG in phosphate-buffered saline for 45 minutes at 37°C. Nonspecific binding sites were blocked with 2% bovine serum albumin in phosphate-buffered saline for 30 minutes at 37°C. After each incubation, the plates were washed three times with phosphate buffered saline. Color was developed by the addition of 100 fLL of a I mg/mL solution of the horseradish peroxidase substrate, 2,2' -azinobis(3-ethylbenzthiazoline-6-sulfonic acid) (lmmuno Pure ABTS; Pierce Chemical, Rockford, IL, U.S.A.). The re action was stopped after 5 minutes by the addition of an equal volume of I % sodium dodecyl sulfate to each well. The optical density of the developed color was read at 405 nm by using a SpectraMAX (Molecular Devices, Menlo Park, CA, U.S.A.) microplate reader.
ELISA assays for IL-8, MCP-I, and IL-I J) were performed as described by Zhang et al. (1999) . The ACM or endothelial cell media were centrifuged at 14,000 rpm for 5 minutes at 4°C and an aliquot (100 fLL) was used in ELISA. The levels of IL-8, MCP-l , IL-I J), and tumor necrosis factor-a (TNF-a) were de termined by using commercially obtained ELISA kits (Bio Source, Camarillo, CA, U.S.A.). ELISA data were corrected for the levels of chemokines/cytokines present in (control or hyp oxic) ACM applied to HCECs. The assays were performed according to the manufacturer's instructions in at least three independent experiments.
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FIG. 2. The effects of the media con ditioned by either control (Con-ACM) or hypoxic (Hyp-ACM) fetal human astrocytes (FHAS) on the expression of ICAM-1 protein in human cerebral endothelial cells (HCEC) determined by immunocytochemistry (A) and ELISA (8). HCEC were exposed to basal media, Con-ACM, or Hyp-ACM prepared as described in Materials and Methods for 24 hours. Bright-field micrographs (A) show negative con trol in which secondary antibody was omitted and HCEC exposed to basal media (Basal), Con-ACM, and Hyp ACM for 24 hours. (8) ICAM-1 levels in HCEC exposed to the same condi tions were determined by ELISA in two separate experiments as de scribed in Materials and Methods. Each bar represents the mean ± SO of quadruplicate ELISA determina tions. 'indicates a significant differ ence (P < 0.01; analysis of variance followed by the Fisher's protected least square difference multiple com parisons) from corresponding basal and Con-ACM levels.
-E r::: : HCEC. HCEC were exposed to Con-ACM or Hyp-ACM prepared as described in Materials and Methods for the indicated periods of time. IL-8 and MCP-1 mRNA were determined by RT-PCR using J3-actin as an internal control. Volumes of IL-8 and MCP-1 bands for Con-ACM (open bars) and Hyp-ACM (closed bars) were expressed as a percentage of J3-actin bands amplified in same PCR reactions. Each bar represents the mean ± SO de rived from three separate gels. *indicates a significant difference (P < 0.01; analysis of variance followed by the Fisher's protected least square difference multiple comparisons) from correspond ing time-matched Con-ACM levels.
Reverse transcription polymerase chain reaction
Total RNA was isolated from FHAS and HCECs grown on 35-mm dishes by using 500 j.1L/dish Tri reagent (Sigma, St. Louis, MO, U.S.A.) following the manufacturer's instruction. The RNA pellets were resuspended in 50 j.1L of diethyl poly carbonate-treated dH20 and incubated at 55°C for 10 minutes. The quality of the RNA was confirmed for each sample by the use of formaldehyde-agarose gel electrophoresis. RNA (0.5 fLg) was then mixed with 0.5 fLg of 0Iigo(dT)12_18 primers, heated for 10 minutes at 70°C, and then chilled on ice. First strand cDNA synthesis (reverse transcription) was performed 971 (20 fLL reaction) as described (Zhang et aI., 1999) and 20 fLL of cDNA was then diluted with 20 fLL of dH20. Specific prim ers for human IL-II3, IL-I RI, ICE, TNF-a, IL-8, MCP-I, ICAM -I, and the housekeeping gene l3-actin were designed according to published sequences from the GenBank (Table I) and were synthesized by using a PerSeptive Biosystem Syn thesizer (Framingham, MA, U.S.A.). The polymerase chain re action (PCR) amplifications were performed in a final volume of 50 J.1L containing Ix reaction buffer (Promega), 1.5 mmollL MgCI, 0.2 J.1mollL dNTPs, 0.4 fLmollL each of the primers, 2.5 units of Taq DNA polymerase (Promega, Madison, WI, U.S.A.), and eDNA. All amplifications were performed by us ing a denaturation step at 94°C for 30 seconds, an annealing step at 5SOC for 45 seconds, and a polymerization step at noc for 40 seconds.
To obtain a linear range of genes listed in Table 1 and l3-ac tin, serial dilutions of eDNA preparation from the cells (HCECs and FHAS) were PCR-amplified for 20 to 45 cycles. The re sultant PCR products were run on a 1% agarose gel, stained with ethidium bromide, photographed, and scanned with the use of a laser Computing Densitometer (Model 300A; Molecu lar Dynamics, CA, U.S.A.). Standard curves of various prod ucts and l3-actin were then generated, indicating a linear range of each "target" gene and l3-actin amplification for each cell type. All experiments are subsequently performed by using conditions optimized for linear amplification. MCP-l and l3-actin were amplified in one tube by using 2-J.LL of cDNA diluted as herein described (i.e., 1: 1, v/v, with dH20) in a 50-J.LL reaction for 25 cycles. IL-8 and l3-actin amplification was performed in the same PCR reaction con taining 5 J.LL of diluted cDNA for 35 cycles. In both cases, 10 J.LL of the PCR product was then subjected to gel electropho resis as described herein. IL-II3, ICE, TNF-a, and ICAM-I were amplified by using 10 J.LL of diluted cDNA, and IL-I RI by using 15 J.LL of diluted cDNA for 45 cycles. Internal control (l3-actin) for these genes was amplified by using I J.LL of di luted cDNA in a 50-J.LL reaction for 45 cycles. Equal amounts of internal control and IL-II3, ICE, TNF-a, IL-8, or ICAM-I PCR products were then mixed and subjected to electrophoresis on a 1.5% agarose gel in I x Tris-boratelEDT A buffer contain ing 0.5 J.Lg/mL ethidium bromide and then photographed. The relative densities/volumes of the bands on film negatives were measured by using a Computing Densitometer (Model 300A; Molecular Dynamics, Sunnyvale, CA, U.S.A.) and analyzed by using ImageQuaNT, version 4. 1, software (Molecular Dynam ics). Various gene products were expressed as percentages of the l3-actin band volume.
RESULTS
Stimulation of proinflammatory genes in HCECs by hypoxic ACM
To test the hypothesis that hypoxic astrocytes secrete factor(s) capable of triggering pro inflammatory activa tion of HCECs, we used an in vitro paradigm in which FHAS cultures were subjected to hypoxiaireoxygenation, and the effects of media conditioned by these cells (ACM) on the expression of inflammatory genes (i.e., adhesion molecules, cytokines, and chemokines) in HCECs were examined. None of various protocols used affected the viability of either FHAS or HCECs as de termined by the exclusion of the vital dye CFDA-AM (Molecular Probes, Eugene, OR, U.S.A.) (data not shown).
ICAM-l. The expression of ICAM-I mRNA in HCECs exposed to hypoxic ACM was up-regulated at 4, 8, 18, and 24 hours after the addition of hypoxic ACM, compared with ACM from normoxic FHAS (Fig. I) . In parallel, immunocytochemical staining for ICAM-I demonstrated an up-regulation of ICAM-I protein in cells exposed to hypoxic ACM for 24 hours ( Fig. 2A) shown as both an increased number of immunopositive cells and a higher intensity of cell staining ( Fig. 2A) . The levels of ICAM-l protein expression were quantified by ELISA in two independent experiments (Fig. 2B) . A twofold increase of ICAM-I levels was observed in HCECs exposed to hypoxic ACM for 24 hours compared with cells exposed to control ACM for the same period of time (Fig. 2B) . ICAM-l up-regulation is considered a J Cereb Blood Flow Metab, Vol. 20, No.6, 2000 hallmark of pro inflammatory endothelial phenotype (Carlos and Harlan, 1994; Kishimoto and Rothlein, 1994) . HCECs have previously been shown to up regulate ICAM-l when stimulated with cytokines, in cluding IL-113 (Stanirnirovic et aI., 1997a,b) .
Chemokines. Hypoxic ACM was found to up-regulate both IL-8 (Fig, 3A) and MCP-l (Fig, 3B) 4, 8, 18, and 24 hours after addition of hypoxic ACM to HCECs ( Fig. 2A & B) . The levels of immunoreactive IL-8 secreted in media of HCECs exposed to hypoxic ACM were significantly higher than those measured in HCECs exposed to control ACM (Fig. 4A) . The increased release of IL-8 from HCECs exposed to hypoxic ACM was apparent as early as 4 hours, reached maximum at 8 hours, and was con tinuously elevated to 24 hours after ACM addition. The levels of MCP-l released by HCECs exposed to hypoxic ACM were five-to sevenfold higher from control at 4 to 8 hours ( Fig. 3B ) and remained elevated to 24 hours (Fig.  4B ).
IL-l � and IL-IRI. The exposure of HCECs to ACM from hypoxic FHAS resulted in the up-regulation of IL-113 mRNA over the entire 4-to 24-hour period examined (Fig. SA) . In contrast, the same hypoxic ACM down regulated mRNA of IL-lRI, a signaling form of IL-ll3 receptor (Fig. 5B) . A similar decrease in the IL-IRI mRNA expression was also seen in HCECs exposed to 100 UNITS/mL IL-ll3 for the same duration (Fig. 5B ). The downregulation of IL-l RI by exogenous IL-ll3 has previously been shown in other cell types (Yu et aI., 1997) . These data suggested that mediators released in hypoxic ACM act on HCECs in a manner similar to that of IL-ll3.
Effects of hypoxia on expression of IL-l� and ICE in human astrocytes
To explore the possibility that IL-113 is an active com ponent of hypoxic ACM that induces inflammatory HCEC phenotype, we examined the effect of hypoxia on the expression of IL-ll3 and other components of the IL-ll3 system in FHAS.
Hypoxia/reoxygenation was found to induce ICE mRNA in FHAS (Fig. 6A ), which suggests that an active form of IL-ll3 could be produced/secreted by hypoxic FHAS. Indeed, IL-113 mRNA was found to be transiently up-regulated in FHAS at 4 hours and 18 hours of reoxy genation after a 4-hour hypoxia (Fig. 6B) . The levels of immunoreactive IL-ll3 secreted into FHAS-conditioned media were elevated at 4, 18 and 24 hours of reoxygen ation (Figure. 6C) .
In addition to IL-II3, TNF-a mRNA was also up regulated in hypoxic FHAS (data not shown). However, we failed to detect immunoreactive TNF-a (detection limit, 50 pg/mL) in ACM from either control or hypoxic FHAS (data not shown). TNF-a hypoxia-stimulated IL-l!3 mRNA expression in FHAS ( Fig. 7 A) . The levels of immunoreactive IL-l!3 secreted in hypoxic ACM of DEX-treated FHAS were reduced to control values at 24 hours of reoxygenation (Fig. 7B) . DEX has been shown to selectively inhibit the expres sion of IL-l!3 at both transcriptional and posttranscrip tional levels in other cell types (Colotta et al., 1998; Kern et al., 1988; Knudsen et al., 1987; Lee et al., 1988) .
The ability of ACM from DEX-treated FHAS to in duce inflammatory genes in HCECs was examined. DEX was added to astrocytes 45 minutes before hypoxia, and media were changed after a 4-hour hypoxic period. Me dia were conditioned over a 24-hour reoxygenation pe riod in the absence of DEX. HCECs exposed to ACM from DEX-treated control FHAS showed lower expres sion of both IL-l!3 and TNF-a mRNA (Fig. 7C ) com pared with control ACM. Furthermore, ACM from DEX treated hypoxic FHAS failed to up-regulate either IL-l!3 or TNF-a mRNA in HCECs (Fig. 7C) . ACM from DEX treated hypoxic FHAS also failed to up-regulate IL-8, MCP-l, and ICAM-l mRNA in HCECs (data not shown). Additional evidence linking IL-l!3 to the ability of hypoxic ACM to trigger a proinflammatory HCEC acti vation was obtained by using IL-l!3 receptor antagonist (lL-IRa) (R&D Systems, Minneapolis, MN, U.S.A.) to inhibit ACM-induced responses in HCECs. IL-IRa binds to both IL-IRI and IL-RII receptors and has been shown to inhibit IL-l !3-induced responses in various cell types (Arend et al., 1998; Dinarello, 1994 Dinarello, , 1998 .
HCECs were incubated with ACM from either control or hypoxic FHAS in the absence or presence of 50 ng/ mL IL-IRa. This concentration of IL-IRa was shown to inhibit 50 UNITS/mL IL-l !3-induced IL-8 and ICAM-l expression in HCECs (data not shown). IL-IRa com pletely inhibited hypoxic ACM-induced ICAM-l, IL-8, and MCP-l mRNA expression (data not shown). Hyp oxic ACM induction of ICAM-l protein in HCECs was completely prevented in the presence of IL-l Ra at 24 hours of exposure (Fig. 8A ). In addition, ACM pretreated with the neutralizing anti-IL-l!3 antibody (R&D Systems. Minneapolis. MN. U.S.A.). but not anti TNF-a antibody (NeoMarkers. Union City. CA. U.S.A.). lost the ability to up-regulate ICAM-l in HCECs (Fig.  8B) . In a similar manner. the secretion of immunoreac tive IL-8 ( Fig. 8C ) and MCP-l ( Fig. 8D) by HCECs was reduced to or below control levels after 4-hour or 24hour exposure to hypoxic ACM in the presence of IL IRa. These experiments provide strong evidence that IL-113 released by hypoxic astrocytes is an important trigger of inflammatory HCEC phenotype.
DISCUSSION
This study demonstrates that hypoxic human astro cytes can evoke proinflammatory activation of human cerebral endothelial cells via mediator(s) secreted/ released in cell media. Proinflammatory activation of HCECs by this paracrine pathway is manifested by the increased expression of the adhesion molecule ICAM-I. cytokines IL-II3 and TNF-a. and the expression and se cretion of chemokines IL-8 and MCP-I. Furthermore. the study provides strong evidence that IL-113 is a pre dominant HCEC-activating mediator secreted by hypox ic astrocytes. This conclusion is based on the following observations: (l) hypoxia up-regulated ICE and IL-ll3 mRNA expression in FHAS and increased secretion of IL-113 into FHAS media; (2) We have previously shown that IL-113 up regulates ICAM-I (Stanimirovic et aI.. 1997a) . vascular cell adhesion molecule-l and E-selectin (Stanimirovic et aI.. 1997 b) . and chemokines IL-8 and MCP-l (Zhang et aI.. 1999) in HCECs. Taken together. these data suggest that IL-113 released from hypoxic astrocytes is a potent paracrine modulator of CEC activation/function in brain ischemia. IL-113 has previously been identified as an important mediator of secondary ischemic brain damage in vivo (Dinarello. 1996; Feuerstein et aI.. 1997 Feuerstein et aI.. . 1998 Rothwell. 1999 ). An exogenous administration of IL-113 was found to exacerbate ischemic brain injury after MCAO in rat (Yamasaki et aI.. 1995) . Animal studies have also shown that the expression of IL-113 is up-regulated between 24 hours and 7 days after focal brain ischemia (Davies et al.. 1999) and that levels of IL-113 expression correlate well with the degree of ischemic brain damage (Feuerstein et a\.. 1998; Rothwell. 1999) . IL-ll3 immunoreactivity in the ischemic brain has been localized to astroglia (Orzy lowska et al.. 1999) . microglia. and scattered perivascu lar macrophages (Sairanen et aI.. 1997 ).
An active form of IL-113 is cleaved from the inactive. 269-amino-acid precursor pro-IL-113 by ICE/caspase I (Arend et al.. 1998; Colotta et aI.. 1998) . Increased levels of IL-113 (Orzylowska et aI.. 1999) and induced expres sion of ICE (Bhat et aI.. 1996) have been detected in animals after focal cerebral ischemia. The inhibition of ICE family proteases (Hara et aI., 1997) as well as ICE gene knockout in mice resulted in the reduction of exci totoxic and ischemic brain injury (Schielke et aI., 1998) .
Several lines of evidence obtained in this in vitro study suggest that astrocytes exposed to hypoxia are a source of IL-I [3. Hypoxia was found to up-regulate ICE mRNA expression in FHAS and this was accompanied by the secretion of immunoreactive IL-l [3 in astrocyte media. In addition, the ability of hypoxic astrocytes to induce pro inflammatory genes in HCECs in a paracrine manner correlated well with the hypoxic stimulation of IL-l [3 expression and release by FHAS.
Both HCECs and FHAS were found to express a sig naling receptor for IL-l [3, i.e., IL-IRI, and IL-IRI down regulation was observed in response to exogenous addi tion of IL-I [3 and hypoxic ACM. IL-I RI is a receptor that mediates all the biological activities of IL-l [3 and ex (Colotta et aI., 1998; Dinarello, 1998; Rothwell, 1999) , and IL-l RI downregulation by the ligand, IL-l [3, may be a potentially important control mechanism that limits propagation of inflammatory response. The expression of IL-IRI has previously been demonstrated in rat cerebral endothelial cells (Van Dam et aI., 1996) . Recently, an increase in IL-IRI mRNA was detected in the hippocam pus 8 to 24 hours after a transient global brain ischemia (Sairanen et aI., 1997) , and in the cerebral cortex 5 days after MCAO (Wang et aI., 1997) in the rat, which sug gests that neurons in discrete areas are target cells for IL-l[3. IL-IRI expression by HCECs and FHAS shown in this study indicates that these cells are also likely targets of IL-l [3 in the brain. DEX, a "classic" inhibitor of IL-l [3 in various cell types (Kern et aI., 1988; Knudsen et aI., 1987; Lee et aI., 1988) , was observed to simultaneously inhibit hypoxia induced IL-l [3 expression/release in FHAS and the abil ity of hypoxic ACM to effect HCEC activation. This provides further evidence that IL-I [3 is an active com ponent of ACM involved in stimulation of inflammatory genes in HCECs. Finally, IL-IRa, a selective and spe cific endogenous receptor antagonist that binds IL-IRI and blocks actions of both IL-l ex and IL-l [3 (Arend et aI., 1998; Dinarello, 1998; Rothwell, 1999) , eliminated the up-regUlation of inflammatory genes and secretion of inflammatory mediators from HCECs induced by hyp oxic ACM, which suggests that IL-l [3 released into hyp oxic ACM triggers proinflammatory activation of HCECs. Blockade of IL-l function in vivo by infusion of IL-IRa rat (Garcia et aI., 1995) , or topical administration of anti-IL-l [3 antibody (Yamasaki et aI., 1995) , has been shown to significantly reduce infarct lesion, neuronal death, and neutrophil infiltration after MCAO. In a re cent study, mice overexpressing IL-l Ra showed a reduction in ICAM-l-positive brain vessels after perma nent focal ischemic insult (Yang et aI., 1999) . These J Cereb Blood Flo'''' Metab, Vol. 20, No.6, 2000 studies and evidence presented in this study implicate IL-l [3 as an important mediator of both ischemic inflam matory changes in cerebral vasculature and ischemic brain damage.
In addition to IL-I [3, in vitro hypoxia was also found to increase the expression of TNF-ex mRNA in FHAS but no immunoreactive TNF-ex was detected in ACM. Other studies have demonstrated that TNF-ex is present as a biologically active membrane-bound form in many cell types and only a small amount of the membrane-bound TNF-ex is cleaved by a metalloproteinase(s) into a free form (Decoster, et aI., 1995; Grell et aI., 1995) . In a similar manner, IL-lex, in contrast to IL-l [3, has been localized in cell cytosol and associated with cell mem branes and is not released into cell media (Colotta et aI., 1998) . These observations suggest that TNF-ex and IL-lex are not significant mediators of HCEC activation by hyp oxic ACM. This is supported by the observation that the antibody against IL-l [3 effectively prevented hypoxic ACM-induced ICAM-l expression in HCECs, whereas anti-TNF-ex antibody was ineffective. However, we can not completely exclude the possibility that proinflamma tory activation of HCECs is aided by other factors se creted in hypoxic ACM, notably IL-8 (Zhang et aI., 1999) .
The in vitro experimental paradigm used in this study bears significant differences from in vivo models of stroke. Several important components of stroke in vivo, such as blood "flow," acidosis, vascular reactivity, and changes in blood rheology, are absent in cell culture models. Furthermore, brain endothelial cells in vivo are exposed to various paracrine sources of "proinflamma tory" mediators including those released by smooth muscle cells, pericytes, and perivascular macrophages. Whereas, in vivo, even small amounts of mediator re leased in intercellular spaces can reach very high local (i.e., physiologically relevant) concentrations, mediators released into ACM are substantially diluted when ap plied to HCECs. For example, in vivo, brain microvessels are enveloped by astrocytes and close proximity of the two cell types would allow for much higher local con centrations of IL-l [3 than those reached in conditioned media. This combination of factors may account for dis crepancies in the magnitude of changes in any particular endotheli al gene observed in this study and those seen in in vivo studies, notably multifold increases in ICAM-l expression observed in microvessels in in vivo models of stroke (Wang et aI., 1994) .
Close apposition of CEC and astrocytes, which invest 99% of the abluminal surface of the capillary basement membrane in the brain in vivo, provides for the anatomic proximity necessary to exert paracrine interactions. Evi dence from grafting experiments, developmental studies, and culture models demonstrate inductive influences of perivascular astrocytes on brain endothelium and vice versa (Abbott et aI., 1992) . Therefore, cooperation be tween two cell types is likely involved in initiating mi crovascular and inflammatory responses to ischemia. Peripheral leukocyte mobilization into the ischemic brain is critically dependent on the "inflammatory" status of CEC including CEC expression of adhesion molecules and chemokines. Our previous studies have shown that HCECs "activated" by simulated in vitro ischemia or exogenous IL-l i3 up-regulate the expression of ICAM-l, avidly bind freshly isolated neutrophils in an ICAM-l/ CD I8-dependent manner (Stanimirovic et ai., 1997 a) , and release potent chemoattractants that stimulate neu trophil chemotaxis in vitro (Zhang et aI., 1999) . A main tenance/enhancement of this initial activation is likely mediated via paracrine cytokines released by neighbor ing cells. Based on the results of this study, it seems that cerebral endothelium is an important target for IL-I i3 produced by hypoxic perivascular astrocytes. The ability of IL-1Ra to reduce ischemic damage in vivo (Garcia et aI. , 1995) is probably, in part, the result of both attenu ated CEC activation via IL-I i3 produced by perivascular astrocytes and reduced leukocyte infiltration into the brain. Therefore, therapies that target endothelial IL-l RI or reduce the production/release of IL-l i3 by glial cell compartment may be successful strategies to alleviate postischemic brain inflammation and secondary brain damage.
